I don't care what color the sniper was blue green black white or orange to do what he did he was one crazy nut who had to be sick in the head. My wife is a mental health therapist and she comes home everyday telling me what type of patients she saw that have no business walking the streets. They are not mentally sound and could go off at any moment. Very scary
N America has sadly largely created this and treatment answers r handed over to big pharma. Health care's greatest failure, or should i say, saddest is its management/diagnosis of mental illness. See, a significant treatment modality is pharmacology -let's treat the ' mentally ill' with a pill-- this pill will provide the coping skills to adapt in the go go go N America hectic lifestyle . How is a pill going to do that? Of course , it can't. And it oftens makes a situation worse . To say nothing of its side effects. Gets extra insane when polypharmacy is used; multiple medications. Patients become zombies.
USA's
NUMBER ONE medication by sales in 2014? Abilify
http://www.medscape.com/viewarticle/825053
'Aripiprazole, sold under the brand name Abilify among others, is an atypical antipsychotic. It is recommended and primarily used in the treatment of schizophrenia and bipolar disorder.[SUP][5][/SUP] Other uses include as an add-on treatment in major depressive disorder, tic disorders, and irritability associated with autism.[SUP][6][/SUP] According to a Cochrane review, evidence for the oral form in schizophrenia is not sufficient to determine effects on general functioning.[SUP][7][/SUP] Additionally, because many people dropped out of the medication trials before they were completed, the overall strength of the conclusions is low.[SUP][7]'
[/SUP]
then there's 'depression'- it's overdiagnosis is a GROSS shame to N America. Projected leading cause of disability by 2025. They have sub-sections of depression such as Seasonal affective disorder (SAD)
. Psychiatry needs to label everything. If a Dept head of Psychiatry walked into The Rx, we'd all likely be on meds. 'hey, did you know you have symptoms of.....?.....'...:missingte . The FDA? have a look:
http://www.ncbi.nlm.nih.gov/pubmed/19339358
'The report is part of the National Institute of Mental Health-funded Sequenced Treatment Alternatives to Relieve Depression (STAR*D) project – the largest study of the treatment of depression conducted in the United States. It showed that findings from clinical studies used to gain FDA approval of antidepressants are not applicable to most patients with depression.
Researchers at the University of Pittsburgh Graduate School of Public Health compared symptoms and outcomes in depressed patients who met phase III study inclusion criteria to those who did not. Phase III studies for antidepressants determine the effectiveness of the drug in comparison to a placebo.
The inclusion criteria for these studies aren’t standardized or subject to any federal guidelines. Typically this means that patients with milder forms of depression, chronic depression, or other psychiatric or medical conditions in addition to short-term depression are excluded from studies.
In other words, the majority of “real world” patients with depression who end up taking antidepressants are excluded from clinical studies. It should be obvious why this is a problem. In a normal, clinical setting many patients with depression do also have other illnesses, such as diabetes, chronic fatigue syndrome or irritable bowel syndrome (IBS). It’s not unusual for them to have anxiety and insomnia, as well. In fact, it wouldn’t be presumptuous to expect that a depressed person might be suffering from a number of conditions that are either contributing to or caused by their illness.
Yet the only people that “qualify” for the clinical trials which determine whether antidepressants get approved by the FDA are those with short-term depression, no history of depression, no other psychiatric conditions such as anxiety, and no physical illnesses like heart disease or diabetes. This is the only subgroup of the general population for which we have any data on the efficacy of antidepressants.
By the same token, this means is that we have almost no clinical data on how antidepressants work for the “real world” patients who are most likely to be taking them. Indeed, after assessing 2,855 patients treated with citalopram (Celexa), the study authors found that fewer than one in four, or 22.2%, of the patients met the usual criteria for inclusion in phase III clinical trials.'
(note- i'm not saying medications have no use in the management of mental illness. And, please i mean no disrespect to sufferers )